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a,b,cMoroccoBackground: In patients with heart failure, left bundle branch block (LBBB) seems to be associated with an increased
risk of cardiovascular mortality.
Purpose: The purpose of this study is to determine the in-hospital outcome of congestive heart failure patients
with LBBB versus those without.
Methods: We conducted a prospective observational study at the Department of Intensive Care and Rhythmology
at the Mohammed V Military Hospital of Rabat, where 330 patients were admitted for heart failure between January
2008 and September 2012. Screening out patients with missing data yielded a cohort of 274 patients. Among the 274
patients, only 110 had LBBB and a left ventricular ejection fraction lower than 50%. We randomly selected a subset of
110 patients diagnosed as non-LBBB to ensure a significant statistical comparison between LBBB and non-LBBB
patients. We therefore considered two groups in our analysis: 110 heart failure (HF) patients with LBBB and 110
HF patients without LBBB. Patients with incomplete records were excluded.
Results: Male gender was dominant in both groups (82.7% vs. 66.7%, p = 0.005). Patients with LBBB had a higher
prevalence of idiopathic dilated cardiomyopathy (39.1% vs. 4.8%, p < 0.001); and a higher prevalence of previous
hospitalization for heart failure (64.5% vs. 23.3%, p < 0.001). The left ventricular ejection fraction was significantly
lower in the group with LBBB (25.49% vs. 39.53%, p < 0.001). Age, cardiovascular risk factors, rhythmic and throm-
boembolic complications did not significantly differ. In patients with LBBB, 61.8% received cardiac resynchroniza-
tion therapy performed both during the index hospital stay (50.9%) and previously (10.9%). Hospital outcome was
marked by 20 in-hospital deaths in the group with LBBB and eight deaths in the group without LBBB (p = 0.008).
Conclusion: Our analysis emphasizes increased in-hospital mortality and higher disease severity, over a short
period of stay, in heart failure patients with left bundle branch block.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Abbreviations
LBBB left bundle branch block
CRT cardiac resynchronization therapy
LVSD left ventricular systolic dysfunction function
LVEF left ventricular ejection fraction
CHF congestive heart failure
DCM dilated cardiomyopathy
EDD end-diastolic diameter
CAD coronary artery disease
ACE angiotensin converting enzyme
ACEI angiotensin converting enzyme inhibitors
CRT-D CRT-defibrillator
EFICA Etude Française de l’Insuffisance Cardiaque
Aigue
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The prevalence of heart failure (HF) in the wes-tern world is known to be 1–2% [1,2], and the
incidence approaches 5–10 per 1000 persons per
year [3]. However, due to the lack of a national
or regional registry of heart failure, this incidence
is not valid for Africa [4], especially North Africa.
Morocco features only one published monocentric
study that included 1578 patients admitted for
heart failure [5].
Approximately one-third of patients with heart
failure present with conduction disturbances that
result in a QRS greater than 120 ms. Most com-
monly (in approximately 25% of HF patients), this
disturbance is exhibited as a left bundle branch
block (LBBB) pattern [6]. This percentage is signif-
icantly higher than the estimated 1.5% prevalence
of LBBB in the general patient population [7].
LBBB is associated with an increased risk of
cardiovascular morbidity and mortality in patients
with heart failure. The electrical dispersion of ven-
tricular depolarization and conduction delay,
which is manifested by QRS elongation, reflects
the severity of the electrical, structural and
mechanical dysfunction of the left ventricle. LBBB
can be mitigated by cardiac resynchronization
therapy (CRT) in patients with moderate to severe
HF and left ventricular systolic dysfunction
function (LVSD). Many studies have shown left
ventricular reverse remodeling after cardiac
resynchronization therapy for heart failure, partic-
ularly in non-ischemic dilated cardiomyopathy.
The aim of the present study was to estimate the
morbidity and mortality of congestive HF patients
with LBBB versus those without LBBB on an in-
hospital basis.Methods
Study design
We conducted a prospective observational study
at the Department of Intensive Care and Rhyth-
mology of the Mohammed V Military Hospital in
Rabat, where 330 patients were admitted for heart
failure between January 2008 and September 2012.
However, the data for many patients were incom-
plete. After excluding patients with missing data,
we obtained a cohort of 274 patients. Among
these, only 110 presented with LBBB and a left
ventricular ejection fraction lower than 50%. We
randomly selected a subset of 110 patients
diagnosed with non-LBBB to ensure a significant
statistical comparison between LBBB and non-
LBBB patients. Therefore, the two groups in ouranalysis consisted of 110 patients with LBBB and
110 patients without LBBB. Thus, we eliminated
the need for normalizing our two groups, while
still preserving the soundness of our study.
This study only included patients aged 35 years
or older with clinical or echocardiographic
manifestations of heart failure. Patients with a left
ventricular ejection fraction (LVEF) P50% or
incomplete records were not included in this
study.Data collection
Entry into the database required that patients
have a diagnosis of HF, which is clinically defined
as a syndrome in which patients have typical
symptoms (breathlessness, ankle swelling, and
fatigue) and signs (elevated jugular venous
pressure, pulmonary crackles, and displaced apex
beat) resulting from an abnormality in the cardiac
structure or function [8]. The main terminology
used to describe HF is historical and is based on
the measurement of LVEF.
Collected variables included demographic and
clinical characteristics (breathlessness, orthopnea,
paroxysmal nocturnal dyspnea, and peripheral
edema), electrocardiographic and echocardio-
graphic variables, nature of the underlying heart
disease, information on therapy and previous hos-
pitalizations for congestive heart failure (CHF).
The main outcome was the occurrence of major
adverse cardiac events. These events are defined
as death (while determining the mechanism of
death in each group), serious arrhythmia (ventric-
ular tachycardia, ventricular fibrillation), throm-
boembolic complications, cardiogenic shock
(systolic arterial pressure <90 mmHg, persistent
hypotension of at least 30 min, tissue hypoperfu-
sion: oliguria, cold extremities, confusion).
Table 1. General, clinical, laboratory and etiological data of both groups with and without LBBB.
With LBBB Without LBBB P
(n = 110) (n = 110)
Age (years): M ± SD 62.27 ± 7.26 60.58 ± 14.06 NS
Male (%) 82.7 66.7 0.005
Chronic co-morbidity* 54 42 NS
CVx risk factors (%)
Diabetes 40 47.5 NS
Hypertension 40.9 45.8 NS
Smoking 54.5 41.7 0.051
Dyslipidemia 29.1 28.3 NS
Obesity 28.2 25.8 NS
Heredity 2.7 0.8 NS
ECG data (%)
Sinus rhythm 87.3 75.8 0.026
Atrial fibrillation 12.7 17.5 NS
Rx CMG (%) 99.1 80.8 <0.001
Echocardiography (%)
Dilated LV 98.2 41.7 <0.001
LVFP 85.3 58.3 <0.001
Coronary artery disease (%)
CT of LCA 1.8 5.0 NS
1 Vessel CAD 10 23.3 0.007
2 Vessel CAD 12.7 13.3 NS
3 Vessel CAD 20.9 26.7 NS
Etiology of HF (%)
Ischemic heart disease 45.5 70 <0.001
Idiopathic DCM 39.1 4.8 <0.001
Valvulopathy 9.1 15.8 NS
Metabolic DCM 2.7 0.8 NS
LV non compaction CM 3.6 0 0.051
M ± SD, mean ± standard deviation; CVx, cardiovascular; HF, heart failure; Rx CMG, radiological cardiomegaly with cardiothoracic index >0.50; LV,
left ventricle; LVFP, left ventricle filling pressure; CT of LCA, common trunk of left coronary artery; CAD, coronary artery disease; DCM, dilated
cardiomyopathy.
* Chronic co-morbidity, chronic obstructive pulmonary disease, renal failure (serum creatinine .200 mmol/L), malignancy, cirrhosis/liver
dysfunction.
Bold values indicate difference between two groups was considered statistically significant when p < 0.05.
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EPIDEMIOLOGICAL AND EVOLUTIONARY CHARACTERISTICS OF HEART FAILURE IN PATIENTSAt the time of patient enrollment, standard
baseline 12-lead electrocardiograms (ECGs) were
obtained at a paper speed of 25 mm/s. Three
cardiologists measured QRS duration using man-
ual calipers. The durations of three consecutive
QRS complexes were averaged to obtain the final
QRS duration for this analysis. LBBB was defined
as a QRS duration of P120 ms with the following
criteria: broad notched or slurred R wave in leads
I, aVL, V5, and V6 (an occasional RS pattern in V5
and V6 may occur due to displaced transition of
the QRS complex); absent q waves in leads I, V5,
and V6; normal R peak time in leads V1, V2, and
V3 (if R waves are present), and >60 ms leads V5
and V6 [9].
All patients had standard two-dimensional and
Doppler echocardiographic examinations using a
GE Vivid 7 Ultrasound machine. LVEF was deter-
mined via the biplane Simpson method. Anatomic
measurements, valvular lesions, and LV filling
pressure were assessed using standard echocar-diographic criteria [10]. Analysis of left ventricular
dyssynchrony was not performed in this study.
Coronary angiography was performed every
time we suspected coronary artery disease based
on the electrocardiogram or echocardiography.
Selection criteria for CRT were New York Heart
Association (NYHA) functional class II, III and IV
heart failure, QRS duration P120 ms, and a per-
sistently reduced ejection fraction 635%, despite
optimal pharmacological therapy [11].
Statistical analysis
Statistical analysis was performed using the
SPSS Version 13.0 software.
Quantitative variables are expressed as the
mean ± standard deviation. The duration of
hospitalization was expressed as median and
interquartile range. Qualitative variables are
expressed as numbers and percentages.
We compared both groups in a univariate
analysis using Student’s t-test on the quantitative
Table 2. Factors of decompensated HF, therapeutic manage-
ment and evolution of the group with and without LBBB.
With
LBBB
Without
LBBB
P
(n = 110) (n = 110)
Decompensation factor (%)
Not following diet* 24.5 15 NS
Stopping treatment 5.5 2.5 NS
Infection 22.7 19.2 NS
Arrhythmia 12.5 10 NS
Ischemic recurrence 20 37.5 0.004
Other 17.3 14.2 NS
Treatment (%)
Furosemide 58.2 43.3 0.024
Spironolactone 30.9 44.2 0.03
ACE 65.5 49.2 0.013
AIIRB 11.8 29.2 0.001
Beta blockers 66.4 79.2 0.029
Angioplasty 9.1 23.3 0.004
Bypass surgery 13.6 20 NS
Valve surgery 4.5 10.8 NS
CRT 61.8 0 <0.001
Good outcome** (%) 31.8 92.5 <0.001
Complications (%)
Death 18.2 6.7 0.008
Arrhythmic 3.6 1.7 NS
Thrombo-embolic 2.7 5 NS
Congestive HF 64.5 23.3 <0.001
ACE, angiotensin converting enzyme; AIIRB, angiotensin receptor
blockers, CRT, cardiac resynchronization therapy.
* Not following diet: patients who fail to follow up a heart healthy
diet.
** Good outcome: absence of deaths or major cardiovascular events.
Bold values indicate difference between two groups was considered
statistically significant when p < 0.05.
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compare duration of hospitalization between the
two groups. The comparison between the two
groups for qualitative variables was conducted
using the chi-square test.
We used a multiple logistic regression in
multivariate analysis. A difference was considered
statistically significant when p < 0.05.Results
Patient population
The database of patients with and without LBBB
is summarized in Table 1.
The average age of our patients was
61.39 ± 11.34 years; 74.3% were male (171 men, 59
women) with a statistically significant difference
between patients with and without LBBB.
In the pooled group, the incidences of breathless-
ness, orthopnea paroxysmal nocturnal dyspnea
and peripheral edema were 98.2%, 72%, 56.2%,
and 23%, respectively.Themain cardiovascular risk factor in the pooled
group was smoking (47.8%), followed by diabetes
(43.9%), and arterial hypertension (43.5%), with
no difference between the two groups.
Thirty-six patients had a prior myocardial
infarction (26 in the LBBB group and 10 in the
non-LBBB group). The prevalence of idiopathic
dilated cardiomyopathy (DCM) (39.1% vs. 4.8%,
p < 0.001) and previous hospitalization for HF
(64.5% vs. 23.3%, p < 0.001) was higher in patients
with LBBB compared with patients without LBBB.
In the LBBB group, all patients had a QRS dura-
tionP120 ms; 58.18% of them had a QRS duration
>150 ms, and 41.82% had a QRS duration6150 ms.
In the non-LBBB group, 18% of patients had a
right bundle branch block (RBBB), and the QRS
duration did not exceed 120 ms.
The LVEF was significantly lower in the group
with LBBB (25.49% vs. 39.53%, p < 0.001), with a lar-
ger end-diastolic diameter (EDD) (69.20 ± 6.307mm
vs. 55.79 ± 7.49 mm; p < 0.001) and end-systolic
diameter (ESD) (58.13 ± 7.672 mm vs. 41.03 ±
10.37 mm; p < 0.001).
Overall, 198 patients underwent coronary angi-
ography (110 with LBBB and 88 without LBBB).
A higher incidence of coronary artery disease
(CAD), diagnosed by coronary angiography, was
detected in the group of patients without LBBB.
One-vessel CAD cases were found in 28.4% of
patients without LBBB vs. 10% of patients with
LBBB. Two-vessel CAD cases were found in 17%
of patients without LBBB vs. 12.7% of patients with
LBBB. Three-vessel CAD cases were found in
34.2% of patients without LBBB vs. 20.9% of
patients with LBBB, and common trunk of left cor-
onary artery stenosis was found in 6.9% of
patients without LBBB vs. 1.8% of patients with
LBBB. The coronary angiography was normal in
13.5% of patients without LBBB vs. 54.6% of
patients with LBBB.Factors of decompensated heart failure,
complications, and hospitalization outcome
As shown in Table 2, the factors of decompen-
sated heart failure including stopping treatment,
not following diet, infection, arrhythmia, and
ischemic recurrence, were similar in both groups.
A significantly higher proportion of patients
with LBBB were undergoing treatment with furo-
semide and angiotensin-converting enzyme
(ACE) inhibitors, while spironolactone, b-blockers,
and Ca-antagonists were prescribed more fre-
quently to patients without LBBB.
In patients with LBBB, 61.8% received cardiac
resynchronization therapy performed during the
Table 3. Multivariate analysis of factors associated with LBBB.
HR (95% CI) P
CVx history 0.889 0.293–2.697 NS
Left HF 2.802 1.081–7.262 0.034
SR 1.197 0.383–3.745 NS
LVEDD 1.135 1.002–1.286 0.046
LVESD 1.029 0.929–1.140 NS
LVEF 0.965 0.910–1.024 NS
Ischemic heart disease 0.285 0.039–2.070 NS
Idiopathic DCM 4.647 1.094–19.738 0.037
CVx, cardiovascular; HF, heart failure; SR, sinus rhythm; LVEDD, left
ventricular end-diastolic diameter; LVESD, left ventricular end-systolic
diameter; LVEF, left ventricular ejection fraction; DCM, dilated
cardiomyopathy.
Bold values indicate difference between two groups was considered
statistically significant when p < 0.05.
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EPIDEMIOLOGICAL AND EVOLUTIONARY CHARACTERISTICS OF HEART FAILURE IN PATIENTSindex hospital stay (50.9%) as well as previously
(10.9%). Among patients who received CRT, 51%
had a coronary artery disease, 37% had an idio-
pathic DCM, 7% had a valvulopathy, and 5%
had LV non-compaction CM. Sixteen of these
patients also received an implantable cardiovert-
er-defibrillator (ICD) function.
Among patients who received a CRT-defibrilla-
tor (CRT-D), 32% were in NYHA functional class
II heart failure, and 68% were in NYHA functional
class III or IV heart failure.
Hospital outcome was good in 92.5% of the
patients without LBBB vs. 31.8% of patients with
LBBB (p < 0.001). In-hospital death occurred in
18.2% of patients with LBBB vs. 6.7% of patients
without LBBB (p = 0.008).
Among deceased patients in the LBBB group,
55% had a QRS >150 ms. The major cause of these
deaths was the progression of heart failure.
The mechanism of death was progression of
heart failure in 58% of patients with LBBB vs.
62% of patients without LBBB, and sudden death
in 42% of patients with LBBB vs. 38% of patients
without LBBB.
Six patients died after receiving CRT. One died
as a consequence of implantation, and five died
despite CRT (cause was heart failure in two cases
and sudden death in the other cases); and 22 died
before they received CRT (cause was heart failure
in 14 cases and sudden death in eight cases).
In-hospital mortality was higher in the non-
CRT-LBBB group compared with the CRT-LBBB
group (32% vs. 8%), with no significant difference
in cardiogenic shock and arrhythmic complica-
tions between the two groups.
In patients with LBBB, there was a higher prev-
alence of cardiogenic shock compared to those
without LBBB (31% vs. 5%), whereas the incidence
of arrhythmic and thromboembolic complications
did not significantly differ.Hospitalization period was longer in patients
with LBBB compared to patients without LBBB
(10 days [8,14] vs. 5 days [5,9], p < 0.001).
In a multivariate analysis, significant factors
associated with LBBB were left-sided HF, LV
EDD, and idiopathic DCM (Table 3).Discussion
Morocco features only one published monocen-
tric study evaluating the epidemiological profile of
patients admitted for chronic heart failure [5]. The
results of the CHU Ibn Rochd study are similar to
our findings in terms of demographic and clinical
characteristics, echocardiographic variables and
causes of heart failure. However, the CHU Ibn
Rochd study did not examine the predictive role
of LBBB in congestive heart failure patients, which
is the scope of our study.
The association of a wide QRS with an increased
mortality rate in CHF has repeatedly been investi-
gated, but results have been conflicting. Neverthe-
less, some studies showed that a wide QRS has an
independent, unfavorable prognostic significance
and increases the mortality rate of patients with
CHF during periods of follow-up examination
extended to five years [12–14]. Other studies that
adopted similar multivariate approaches did not
confirm this finding [15–17]. Such discrepancies
may arise from the variable cutoffs adopted to
define the conduction defect, ranging from a mild
widening of the QRS complex above 120 ms to
complete LBBB [12,14–17], and from large differ-
ences in the covariates included in multivariate
analyses. A further cause of conflicting results
may be represented by the variable cause of CHF
in the various studies which – in most cases – only
included patients with dilated cardiomyopathy
[13,14,17]. Only two studies included a few patients
with ischemic heart disease [12,15]. Alternatively,
clinical presentation upon admission (cardiogenic
shock, blood pressure, and pulmonary edema)
may have influenced the results [18], and some
studies included patients with BBB without distin-
guishing between LBBB and RBBB [19].
Our study is important for several specific rea-
sons. First, our study population is representative
of a general population hospitalized for CHF,
including not only patients with cardiogenic shock
but also those without cardiogenic shock present-
ing either with high blood pressure and pulmon-
ary edema or with lower blood pressure. Second,
our study reports the analysis of an unselected
CHF population with or without previous hospi-
talization for CHF. Third, our study estimates
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LVSD and LBBB while comparing them to patients
with LVSD and non-LBBB on an in-hospital basis.
The baseline clinical characteristics were com-
pared to some studies discussing the same subject
[6,20].
The mean age of our patients was 61.39 years,
while in other studies, age varied between 63
and 73 years. These data suggest that our patients
are younger than those examined in other studies.
In the literature, the prevalence of LBBB also
increases with age [21]. Our study did not show
a statistically significant difference between the
groups with and without LBBB.
Our study included more male patients
(males = 74.3%), which is comparable with the
demographics of other studies. The most encoun-
tered cardiovascular factor was smoking (54.5%) in
the LBBB group, and diabetes in the non-LBBB
group (47.5%).
A direct causal relationship between LBBB and
smoking was not evident. This incidence can be
explained by a higher presence of coronary dis-
ease in smokers. In the sub-study of the Etude
Française de l’Insuffisance Cardiaque Aigue
(EFICA) cohort, the cardiovascular risk factors
were similar in both groups, with hypertension
representing the main risk factor (60%).
A previous hospitalization forHFwas foundmore
often in our analysis (64.5%) than in other studies.
One of the primary causes of heart failure in
Morocco is believed to be rheumatic valvular
heart disease. However, the results of our study
showed that the leading cause is ischemic heart
disease. This finding is due to various factors,
namely, smoking, a diet high in saturated fats, die-
tary habits rich in salt, and obesity.
Ischemic heart disease was the most common
cause of CHF in both groups with and without
LBBB. This finding is consistent with the sub-study
of the EFICA cohort. In the report from the Italian
Network on Congestive Heart Failure, the main
cause of HF was dissimilar between the two
groups, with dilated cardiomyopathy and ischemic
heart disease being themost common diagnoses in
patients with and without LBBB, respectively.
LVEF was significantly lower in the LBBB group
compared to the non-LBBB group. Our findings
are consistent with other studies.
A number of studies have noted an inverse rela-
tionship between the ejection fraction and QRS
duration [22–26]. However, only one study per-
formed a multivariate analysis to determine the
predictors of LBBB [23]. In McCullough PA et al.
study of patients admitted to an intensive careunit with acute heart failure, the significant inde-
pendent predictors were ejection fraction
(p < 0.0001), renal function (p = 0.04) and age
(p = 0.04). In our study, left ventricular ejection
fraction and age were not confirmed as indepen-
dent predictors. However, renal function was not
reported in our study.
The Framingham study specifically showed that
28% of patients who were free from clinical HF
and who developed LBBB after the first Framing-
ham examination also developed HF coincident
with, or soon after, the onset of LBBB. The mean
time interval from the onset of LBBB to the first
recognition of clinical HF was 3.3 years [27,28].
While the Framingham study suggests that HF
might develop as a result of LBBB, HF could also
develop before the block and simply worsen with
increasing conduction disturbances [21].
To the best of our knowledge, the majority of
studies that analyzed the prevalence and the
prognostic impact of LBBB in patients with heart
failure focused on long-term mortality. On the
other hand, our study emphasizes in-hospital
mortality and morbidity of CHF patients with vs.
without LBBB during a short period of stay (the
average length of stay was 10 days in the LBBB
group and five days in the non-LBBB group).
In the recent McCullough PA et al. prospective
study, increased QRS duration was found to be
associated with worse outcome in a population
admitted for acute heart failure (AHF) [23]. Simi-
larly, a retrospective analysis from the Efficacy of
Vasopressin Antagonism in Heart Failure Out-
come Study With Tolvaptan (EVEREST) study
concluded that a prolonged QRS duration was
an independent predictor of high post-discharge
morbidity and mortality following hospitalization
for AHF in patients with a history of CHF and
LVSD (LVEF 6 40%) [29]. In our study, the death
rate was significantly higher in the LBBB group
(18.2% of patients with LBBB vs. 6.7% of patients
without LBBB). This finding suggests that LBBB
is associated with worse hospital outcome in
CHF patients with LVSD, but with no significant
difference between patients with a QRS duration
>150 ms and patients with a QRS duration
6150 ms. The mechanism of death was progres-
sion of heart failure in 58% of patients with LBBB
vs. 62% of patients without LBBB, and sudden
death in 42% of the patients with LBBB vs. 38%
of the patients without LBBB. Notably, the QRS
widening to >120 ms exposes HF patients to more
frequent rhythmic events [30]. However, arrhyth-
mic complications did not significantly differ
between the two groups.
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EPIDEMIOLOGICAL AND EVOLUTIONARY CHARACTERISTICS OF HEART FAILURE IN PATIENTSBecause HF and LBBB share the same etiologies
[31], the treatment of causative diseases, mainly
diabetes, hypertension, and CAD, will be instru-
mental in the prevention of HF as well as the
occurrence of the conduction defect. In our study,
the use of angioplasty and coronary artery bypass
graft (CABG) surgery was low despite a high inci-
dence of CAD. This is due to socioeconomic levels
of patients as well as advanced age or severe
co-morbidities that limit performing these
techniques in our social context.
Although current drug treatments acting on
neurohumoral imbalances can lead to a decrease
in heart volumes and in LV hypertrophy, data
suggesting that these drug treatments can cause
electrical reverse remodeling and thus restore a
normal conduction after LBBB are scarce [21]. On
the other hand, some studies that evaluated
patients treated with current drug regimens iden-
tified a progressive lengthening of QRS duration
[32,33]. The Euro Heart Failure survey recently
showed that in a HF population the QRS was
shorter in patients treated with beta-blockers
(BB), while it was longer in those treated with
angiotensin converting enzyme inhibitors (ACEI),
spironolactone, or digoxin [34]. These findings are
consistent with our results concerning beta-block-
ers and ACEI, but we were limited in prescribing
the BB, ACEI and angiotensin receptor blockers
(ARB) given that certain patients had low blood
pressure (<100/60 mmHg) or acute renal failure.
During the past 15 years, biventricular resynchro-
nization has been validated by various multi-centric
studies and is currently an integral component of
the therapeutic arsenal ofHFpatientswithLBBB [35].
Cardiac resynchronization therapy allows for
significant clinical benefit, reverse remodeling,
reduction of ventricular volumes, and decrease
of morbidity and mortality in patients with symp-
tomatic heart failure and wide QRS [36]. From our
cohort of patients with LBBB, 61.8% received car-
diac resynchronization therapy performed during
the index hospital stay (50.9%) as well as previ-
ously (10.9%). Only 16 of these patients also
received an ICD function, due to several reasons:
the majority of our patients were in NYHA func-
tional class III or IV heart failure, and CRT-D is
preferentially implanted in asymptomatic or
mildly symptomatic patients because they are
younger, have fewer co-morbidities and have a
higher proportion of sudden vs. non-sudden car-
diac deaths; the cost-effectiveness of CRT-D
remains high; and the evidence from trials
remains insufficient to show the superiority of
combined CRT and ICD over CRT alone [37].Current CRT guidelines do not specify the time
of CRT device implantation relative to AHF admis-
sion. The OPTIMIZE-HF trial found that CRT
implantation during an AHF hospitalization was
safe and associated with a decreased rate of re-
admission [38]. Hospitalization for CHF may thus
be a window of opportunity for possible CRT
implantation. LBBB patients with no history of
severe chronic HF could be a potential new target
population in which the relative benefit of CRT
may be higher (and the response rate greater) than
in stable patients with NYHA III and IV severity.
Studies have shown a continuous relationship
between broader QRS and a greater benefit from
implantable cardioverter defibrillator-CRT [39].
The majority of patients who died did not receive
CRT. In patients who received CRT with or with-
out ICD function, 40% had a QRS >150 ms, and
only two died.
Based on the in-hospital increased mortality
observed in the non-CRT group, we support the
view that CRT combined with optimal pharmaco-
logical therapy has a highly favorable and sus-
tained impact on mortality.Limitations
Our study was limited to one center in Morocco,
and included a limited number of patients. This is
an in-hospital based study that only describes
hospital outcome with no real post-hospital fol-
low-up as the majority of considered patients
either never followed up with the center or were
transferred to other private practices or centers.
To the best of our knowledge, this work is the
first Moroccan in-hospital study to examine the
predictive role of LBBB in CHF patients. As a
result, we observed that in-hospital mortality
and disease severity, recorded in a short time
interval, are higher with LBBB.Conclusion
In conclusion, our hospital-based study indicates
that complete LBBB is unequivocally associated
with higher in-hospital mortality and greater dis-
ease severity, recorded in a short time interval, in
patients with CHF and reduced left ventricular
systolic function. The significant factors associated
with LBBB in a multivariate analysis were left-
sided heart failure, LV end-diastolic diameter,
and idiopathic DCM. The ECG remains an accessi-
ble and inexpensive tool in the identification of this
electrical abnormality, underscoring the impor-
tance of QRS duration in the selection of patients
FU
LL LEN
G
TH
 A
RTIC
LE
8 BOUQATA ET AL
EPIDEMIOLOGICAL AND EVOLUTIONARY CHARACTERISTICS OF HEART FAILURE IN PATIENTS
J Saudi Heart Assoc
2015;27:1–9for cardiac resynchronization therapy to improve
prognosis and relieve symptoms.References
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